ECMO treatment

FDA clearance for extracorporeal life support system

The U.S. Food and Drug Administration (FDA) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for patients with acute lung failure or acute cardiopulmonary failure.

product photo of novalung device
The Novalung system
Source: Fresenius Medical Care

With Class II approval, the Novalung system is the first complete system approved for ECMO therapy (ECMO = extracorporeal membrane oxygenation) and long-term use for a duration of more than six hours. This enables physicians to provide their patients suffering from acute lung failure or acute cardiopulmonary failure with ECMO therapy over a longer period of time using a single device. In addition, the Novalung system can be used to apply extracorporeal CO2 removal (ECCO2R) for severe lung diseases.

The whole system consists of the Novalung console and the XLung kit. The market launch in the U.S. is planned for the middle of this year.

"The approval is an acknowledgement of the high quality standard of our products to which we are committed as part of Fresenius Medical Care," explains Andreas Terpin, CEO of Xenios, and adds: "A particular success for us is the wide range of the approval from ECMO to ECCO2R.”

The clearance of the Novalung system was strengthened by clinical data from a retrospective analysis of approximately 150 patients who had received ECMO treatment. According to the FDA, the results showed that the Novalung system's clinical efficacy and safety supports a long-term ECMO treatment and that the system is suitable for the entire spectrum of venovenous and venoarterial support.

Source: Xenios


Read all latest stories

Related articles


Point-of-Care ultrasound

Diving deep with POCUS

Costantino Balestra, Professor of Physiology at Haute Ecole Bruxelles-Brabant in Belgium, uses point-of-care ultrasound (POCUS) in environments that could not be more different from a typical…


Xenios consoles as lifesavers

ECMO: crucial in the battle against COVID-19

As the coronavirus spreads and infections with COVID-19 further increase throughout Europe, ECMO therapy turns out to be a necessary option for patients with severe courses. Xenios AG, a subsidiary…


Turning hidden depths into meaningful answers

Agfa launches digital tomosynthesis solution

Agfa announces the launch of its digital tomosynthesis solution, which offers a fast, economical and low-dose technique to separate anatomical overlap in a variety of applications. Powered by Musica,…